Aker BioMarine AS, a biotechnology company, develops krill-derived ingredients and products for nutraceutical, aquaculture, and animal feed applications. More Details
Reasonable growth potential with imperfect balance sheet.
Share Price & News
How has Aker BioMarine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AKBM-ME is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: Insufficient data to determine AKBM-ME's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how AKBM-ME performed against the Norwegian Food industry.
Return vs Market: Insufficient data to determine how AKBM-ME performed against the Norwegian Market.
Long-Term Price Volatility Vs. Market
How volatile is Aker BioMarine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Aker BioMarine undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: AKBM-ME (NOK106.14) is trading above our estimate of fair value (NOK45.42)
Significantly Below Fair Value: AKBM-ME is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AKBM-ME is unprofitable, so we can't compare its PE Ratio to the NO Food industry average.
PE vs Market: AKBM-ME is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKBM-ME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKBM-ME's PB Ratio (2.6x) is in line with the NO Food industry average.
How is Aker BioMarine forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKBM-ME is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: AKBM-ME is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AKBM-ME's is expected to become profitable in the next 3 years.
Revenue vs Market: AKBM-ME's revenue (17.4% per year) is forecast to grow faster than the Norwegian market (6.1% per year).
High Growth Revenue: AKBM-ME's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AKBM-ME's Return on Equity is forecast to be low in 3 years time (17.1%).
How has Aker BioMarine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKBM-ME is currently unprofitable.
Growing Profit Margin: AKBM-ME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKBM-ME is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare AKBM-ME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKBM-ME is unprofitable, making it difficult to compare its past year earnings growth to the Food industry (18.4%).
Return on Equity
High ROE: AKBM-ME has a negative Return on Equity (-7.16%), as it is currently unprofitable.
How is Aker BioMarine's financial position?
Financial Position Analysis
Short Term Liabilities: AKBM-ME's short term assets ($194.0M) exceed its short term liabilities ($69.5M).
Long Term Liabilities: AKBM-ME's short term assets ($194.0M) do not cover its long term liabilities ($255.4M).
Debt to Equity History and Analysis
Debt Level: AKBM-ME's debt to equity ratio (59.7%) is considered high.
Reducing Debt: AKBM-ME's debt to equity ratio has reduced from 208.1% to 59.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKBM-ME has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AKBM-ME has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year
What is Aker BioMarine current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKBM-ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKBM-ME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKBM-ME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKBM-ME's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKBM-ME's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Matts Johansen (44 yo)
Mr. Matts Johansen has been Chief Executive Officer at Aker BioMarine ASA since July 1, 2015. Mr. Johansen has been Chief Operating Officer of Aker Biomarine Antarctic AS since June 1, 2012. He serves as P...
CEO Compensation Analysis
Compensation vs Market: Matts's total compensation ($USD0.00) is below average for companies of similar size in the Norwegian market ($USD571.30K).
Compensation vs Earnings: Matts's compensation has been consistent with company performance over the past year.
|Director||4.75yrs||no data||no data|
|Director||4.75yrs||no data||no data|
|Director||4.75yrs||no data||no data|
|Employee Representative Director||1.25yrs||no data||no data|
|Employee Representative Director||0.42yr||no data||no data|
Experienced Board: AKBM-ME's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AKBM-ME insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: AKBM-ME only recently listed within the past 12 months.
Aker BioMarine AS's company bio, employee growth, exchange listings and data sources
- Name: Aker BioMarine AS
- Ticker: AKBM-ME
- Exchange: OB
- Industry: Packaged Foods and Meats
- Sector: Food, Beverage & Tobacco
- Market Cap: kr9.109b
- Shares outstanding: 87.59m
- Website: https://www.akerbiomarine.com
Number of Employees
- Aker BioMarine AS
- OksenOeyveien 10
- PO Box 496
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AKBM-ME||OB (Oslo Bors)||Yes||Ordinary Shares||NO||NOK||Jul 2020|
Aker BioMarine AS, a biotechnology company, develops krill-derived ingredients and products for nutraceutical, aquaculture, and animal feed applications. The company provides krill oil products, including ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 17:22|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.